The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome, which has a 5% to 15% fatality rate and affects tens of thousands of people annually. Currently no vaccine is available.
PharmaJet's delivery device was chosen for this Phase 1 trial after pre-clinical studies with similar vaccines showed significantly higher (tenfold increase) immunogenicity with the needle-free device, as compared to needle and syringe, and comparable results to electroporation.
PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.
The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needle stick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project